Author: Nancy Meredith
World Health Organization Reiterates All Forms of Asbestos Cause Cancer
The World Health Organization and the International Agency for Research on Cancer issued a joint statement Feb. 19 stating that all forms of asbestos cause cancer in humans and stopping the use of all forms of asbestos is the most efficient way to eliminate diseases caused by asbestos such as mesothelioma, a cancer of the lining of the chest and abdominal cavities.
The joint statement came in response to an article published this month in The Lancet medical journal raising questions about the IARC ‘s participation in a conference in Kiev, Ukraine and potential conflicts of interest. The IARC is participating with the Russian Scientific Research Institute of Occupational Health in a study of cancer among chrysotile workers in Asbest, Russia. The lead author of the research is Evgeny Kovalevsky, who is a promoter of chrysotile asbestos. The IARC is providing epidemiological expertise for the study.
Several prominent American health researchers including Richard Lemen, retired U.S. Assistant Surgeon General, sent a letter to the IARC saying it was unacceptable that a scientist who is a promoter of asbestos should be a lead investigator on an IARC research project. The authors of the letter noted that the World Health Organization had previously withdrawn the Russian Scientific Research Institute’s designation as a WHO collaborating center because of the institute’s conflicts of interest with the Russian asbestos industry.
In the joint statement, the WHO and IARC said the study on cancer among chrysotile asbestos workers in Asbest, Russia will provide important scientific data to quantify the risk of cancers known to be related to chrysotile, the most commonly produced asbestos fiber. In addition it may be useful in quantifying the risks of additional cancers suspected to be related to chrysotile asbestos exposure. The IARC acknowledged receiving a number of emails urging the agency not to participate in the conference.
The IARC and WHO said they take conflict of interest seriously and use a rigorous process to protect research.
According to the Lancet article, the timing of the IARC attendance at the conference and decision to collaborate in the study are particularly sensitive on the eve of an upcoming meeting of countries participating in the Rotterdam Convention. The attendees at the conference will discuss the listing of chrysotile to the Rotterdam Convention, which would require countries that import chrysotile asbestos to give prior informed consent of the health hazards it poses. Russia which has an active asbestos industry, may try to block the addition to chrysotile to the list of hazardous substances.
The heaviest burden of asbestos cancer is currently found in the United State, European countries, Australia, Japan and South Africa, according to a 2012 article in the British Journal of Cancer. The highest consumption of asbestos is in China, Russian, India, Ukraine, Thailand, Brazil and Iran, signaling that those countries will have increases in mesothelioma and asbestos-related cancer deaths in the future.
Approximately, 2,500 to 3,000 people in the U.S. die each year of mesothelioma. It is a devastating disease. Most people who are diagnosed with mesothelioma were exposed to asbestos in a workplace or during military service decades ago.
Sources :
- Lancet article
http://secure.jbs.elsevierhealth.com/action/cookieAbsent - joint statement
http://www.who.int/mediacentre/news/statements/2013/response_lancet_20130219/en/
Researchers Assess Safety and Effectiveness of New Mesothelioma Drug
Medical researchers at Memorial Sloan-Kettering Cancer Center in New York have treated the first patient with a new experimental vaccinia virus-based cancer therapy designed for patients with malignant pleural mesothelioma or non-small cell lung cancer. Mesothelioma is a cancer of the lining of the chest cavity caused by exposure to asbestos.
Genelux Corp., a biopharmaceutical company that develops vaccinia virus-based cancer therapies, announced in a Feb. 6 press release the treatment of the first patient in the Phase I clinical trial designed to evaluate a drug known as GL-ONC1.
Vaccinia virus cancer therapies are part of an emerging area of medical research that utilizes modified viruses to target and destroy malignant cancer cells. Vaccinia virus produces a potent immune reaction to help destroy tumors. The virus was used extensively during the campaign to wipe out smallpox.
Through the current trial, the New York mesothelioma treatment researchers want to learn more about the safety and effectiveness of the new drug at different dosage levels on cancer patients with malignant pleural effusion. The accumulation of fluid between the thin layers of tissue lining the lung is known as pleural effusion. When the fluid contains cancer cells, it is known as malignant pleural effusion. A buildup of fluid is a complication that occurs in many patients who have pleural mesothelioma or lung cancer.
The clinical trial, which is recruiting patients, will assess the safety and tolerability of GL-ONC1 and the severity of side effects. The primary goal is to assess a safe dosage level. The trial may enroll up to 54 patients.
Dr. Valerie W. Rusch, a leading thoracic surgeon and expert on mesothelioma, is the lead researcher in the clinical trial sponsored by Memorial Sloan-Kettering Cancer Center.
“We are very pleased that researchers at MSKCC have initiated this important trial, “Dr. Aladar A. Szalay, founder and CEO of Genelux Corp., said in a press release. “For the first time, this will allow us to examine the feasibility and effects of administering GL-ONC1 directly into the chest cavity to some of the most aggressive cancers of the thoracic cavity—including mesothelioma and non-small cell lung cancer.”
Szalay said the drug has been well-tolerated and shown promising results in early trials involving human patients against a number of solid tumor cancers.
Mary Hesdorffer, executive director of the Mesothelioma Applied Research Foundation, an advocacy and support group, said novel therapeutic approaches based upon new scientific strategies may lead to more effective treatments and eventually a cure for mesothelioma.
Thoracic Nurse to Provide Mesothelioma Information to Readers of MesotheliomaHelp
Lisa Hyde-Barrett has been a thoracic surgery nurse for nearly 25 years, and has had the privilege of caring for countless mesothelioma patients over the years. Lisa has worked alongside some of the leading authorities on treating mesothelioma at Brigham and Women’s Hospital through the International Mesothelioma Program (IMP).
Lisa is also a wellness advocate and she understands the relationship between awareness and cancer prevention and spends much of her time educating patients and their families about the importance of living a healthy lifestyle. She also knows that mesothelioma is one disease that can only be prevented through avoidance of asbestos, and once it develops it is challenging to treat.
Lisa feels very passionate about focusing her career on caring for mesothelioma patients and helping them deal with the disease. “I think that these people are the bravest people I have ever met,” says Lisa.
She adds that many of the patients that are treated at the IMP come such long distances, some coming from as far away as Europe and Asia, and they have no idea how their fortune is going to turn out. “These people have been given the worst of the worst news, yet still they find hope and courage,” said Lisa.
Lisa also works with Nursing Liaisons. Nursing Liaisons was founded on the premise that highly skilled and educated thoracic nurses recognize the need for a precise “aftercare” program. The nurses not only offer medical care to patients, but they also help to educate patients synchronizing their diagnosis with each unique, individual journey of mesothelioma. The nurses hope to educate patients transitioning to a more meaningful understanding of treatment and prognosis.
Lisa has been called upon to share her knowledge of mesothelioma at various conferences and educational seminars. In September, she co-presented a session at the 11th International Conference of the International Mesothelioma Interest Group entitled, “The Complex Discharge Needs of the Mesothelioma Patient.” She and her colleagues discussed the potential barriers mesothelioma patients and their families may encounter that could impede learning how to care for the patient and how nurses can offer support to help overcome those obstacles.
She is certified in Guided Care which was presented from Johns Hopkins Hospital. Also, Lisa recently has been certified in Reiki, a Japanese “laying on hands” technique for stress reduction and relaxation that promotes healing.
“I continue to meet people fighting this disease, and I am always asking how I can make a difference and help them through this journey,” says Lisa.
Please join us in welcoming Lisa to MesotheliomaHelp where she will offer articles focused on the needs of mesothelioma patients.
Funds from EU to Aid Rare Disease Consortium in Battling Mesothelioma
In 2011, the U.S. National Institutes of Health and the European Commission joined forces to form the International Rare Disease Research Consortium (IRDiRC) with a goal to develop 200 new rare disease treatments by 2020. To support this effort, the EU announced last week it is dedicating nearly 38 million Euro, or more than $51 million, in funding towards “the development of a central global rare disease hub involving 70 institutions that will allow scientists to share data from their genomics research projects.” Rare diseases, such as mesothelioma, globally affect nearly one person in 17.
According to a press release by Newcastle University which is coordinating the new rare disease hub, the collaborative efforts will lead to “faster diagnosis” and better treatments that will improve the quality of life for rare disease sufferers.
In the United States, an orphan disease status is assigned to a disease or disorder if it affects fewer than 200,000 Americans at any given time. Mesothelioma, a cancer caused by asbestos exposure, is diagnosed in 3,000 Americans each year. There are nearly 7,000 rare diseases that affect one in ten Americans. Close to 30 million people across Europe are affected by a rare disease.
Many physicians and scientists believe that the answer to finding an effective treatment for mesothelioma and other rare diseases lies within each patient’s genetic makeup. Recent advances in genome sequencing have brought the cost down and have accelerated genetic discovery leading to targeted drug development and personalized care.
“Being able to sequence a person’s entire genetic code is an important advance, particularly for people living with the many rare genetic disorders, but it has also shown us that sequencing is only the first part of the story,” said Professor Hanns Lochmüller of Newcastle University and leader of the project. “It doesn’t replace clinical expertise – in fact, being able to combine genetic data with clinical data is more important than ever.”
The IRDiRC is launching several major projects combining international genetic data with clinical information and data on biomaterials “to help interpret the vast amounts of data the genome yields,” said Professor Paul Lasko of McGill University in Montréal, Canada, Chair-Elect of the IRDiRC Executive Committee. “This will aid scientists in the search for genetic causes of diseases and help identify new ways to create targeted therapies.”
According to Newcastle University, the projects include developing a global infrastructure to share the research of rare disease projects and supporting international rare disease collaboration through IRDiRC.
The IRDiRC Conference 2013 will be held in Dublin, Ireland on April 16-17, 2013. Sessions will focus on fostering international collaboration in rare diseases research. In addition, attendees will discuss which tools are needed and which are under development that can be used towards reaching IRDiRC objectives.
Student of Optometry Places Third in Mesothelioma Essay Scholarship Contest, Encourages Mesothelioma Patients to Maintain a Positive Attitude
Kim Forgione completed a degree at the University of Montana in wildlife biology, and was anxious to continue her education. However, as she looked to earning a doctorate in optometry she knew that finding ways to help pay for her education would be critical in allowing her to focus on her goal. Fortunately, Kim entered the mesothelioma essay scholarship contest sponsored by MesotheliomaHelp.org and placed third for her essay, “Latest Developments in Mesothelioma Treatment Options,” winning $1,250 to apply towards her PhD program.
“I never take for granted people and organizations that are generous enough to help me in reaching my academic goals,” said Kim after learning of her prize. “The scholarship will help me in meeting the financial challenges of attending optometry school, and it strengthens my obligation to always do my best and live up to my full potential.”
Kim’s essay focused on new developments for the treatment of mesothelioma, an asbestos-caused cancer, such as tomotherapy, an advanced form of radiotherapy, immunotherapy and gene therapy. She concludes saying, “The future of mesothelioma treatment options is hopeful, and new findings can only build upon our current knowledge in revolutionary ways.”
Although Kim had heard of mesothelioma prior to writing her essay, she said, “I am privileged for having the opportunity to engage in a scholarship contest that allowed me to learn so much about such an important topic.” She added that she would tell mesothelioma patients, “to maintain a positive and hopeful attitude.” Treatment options have come a long way over the past few years, she said, and she believes they can only become more advanced in the years to come.
The winning essay writers had a second chance to win an Apple iPad Mini by garnering the most “likes” on MesotheliomaHelp.org’s Facebook page for their winning essays. Kim received a total of 460 votes to win the iPad.
“The iPad will allow me to have numerous optometry-related applications at my finger tips. It will also serve as a convenient means to transport notes, textbooks, and other references to class.”
Kim said she was “honored” to be chosen as one of the winners. Now she will help raise awareness of mesothelioma by directing people to MesotheliomaHelp.org and other appropriate mesothelioma resources.
You can read Kim’s winning essay here.
Free Mesothelioma Patient & Treatment Guide
We’d like to offer you our in-depth guide, “A Patient’s Guide to Mesothelioma,” absolutely free of charge.
It contains a wealth of information and resources to help you better understand the condition, choose (and afford) appropriate treatment, and exercise your legal right to compensation.
Download Now